CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of R/R MM, relapsed/refractory primary plasma cell leukemia (R/R pPCL), relapsed/refractory plasma cell leukemia (R/R PCL), and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT059X, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R/ MM and R/R PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I.